FeesSafety
Pluang+

Forterra poised for earnings rebound after £140M plant upgrade amid UK housing slump

Market News
24 Oct 2026
Seeking Alpha
View Source
Bullish
Forterra poised for earnings rebound after £140M plant upgrade amid UK housing slump

Forterra has completed a £140 million upgrade of its Desford plant, doubling production capacity and setting the stage for a strong earnings recovery as UK housing demand improves. Despite the current severe housing downturn, the company benefits from significant operating leverage, reduced debt of £81 million, and lower capital expenditures of £10 million. Ongoing share buybacks at attractive prices also position Forterra to emerge stronger, with potential owner earnings reaching 28p per share, an 18% yield at current prices. This makes Forterra shares appealing for investors looking for value below £2 amid the market downturn.

Forterra's recent developments provide context for readers interested in market movements. For readers following Basic Materials, here is Pluang's market snapshot as of Oct 24, 2026 19:21 WIB: out of 83 priced US stocks, 30 rose and 51 fell. Notable movers include CDE at USD 13.45 with a 1-day change of -3.10% and 100% buy order activity, SSRM at USD 28.38 down 2.81%, and CRS at USD 284.66 down 2.60% with 100% buy order activity.

More News

Nanobiotix reports promising Phase 1 results for JNJ-1900 in advanced melanoma resistant to anti-PD-1 therapies

Nanobiotix reports promising Phase 1 results for JNJ-1900 in advanced melanoma resistant to anti-PD-1 therapies

Nanobiotix announced positive Phase 1 trial results for JNJ-1900 (NBTXR3), used with radiotherapy and immune checkpoint inhibitors, in 24 heavily pretreated advanced melanoma patients resistant to anti-PD-1 therapies. The treatment showed a 41.7% obj...

Company Fundamentals
Bullish
1 hour ago
Genmab and Incyte launch trial combining petosemtamab and INCB161734 for KRAS G12D metastatic colorectal cancer.

Genmab and Incyte launch trial combining petosemtamab and INCB161734 for KRAS G12D metastatic colorectal cancer.

Genmab and Incyte announced a Phase 1/2 clinical trial to test a combination of petosemtamab, INCB161734, and standard chemotherapy as a first-line treatment for metastatic colorectal cancer with the KRAS G12D mutation. This mutation is common and li...

Company Fundamentals
Bullish
1 hour ago
AirTripMaker launches guide for Business Class flights from the US to 15 global destinations.

AirTripMaker launches guide for Business Class flights from the US to 15 global destinations.

AirTripMaker has introduced a comprehensive Business Class Flight Routes Guide to help travelers from the US explore premium flight options to 15 major international destinations across Asia, Europe, Africa, and Australia. The guide covers airlines, ...

Others
Neutral
3 hours ago
BlackRock TCP Capital remains a sell amid structural challenges despite high dividend yield.

BlackRock TCP Capital remains a sell amid structural challenges despite high dividend yield.

BlackRock TCP Capital (TCPC) continues to face structural issues and sector headwinds, leading to a sell recommendation despite trading at a deep discount to its net asset value (NAV). The company has restructured its portfolio, including a significa...

Market News
Bearish
4 hours ago
Blockstream opens Swiss office to offer Bitcoin infrastructure consulting for European financial firms

Blockstream opens Swiss office to offer Bitcoin infrastructure consulting for European financial firms

Blockstream has opened a new office in Lugano, Switzerland, launching consulting services to help banks and asset managers design and implement Bitcoin infrastructure. The service covers technical planning, system architecture, and integration for pr...

Protocol Fundamentals
Bullish
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App